Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-On Biologics “Integrally Related” To Patent Reform Bill, Sen. Hatch Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Remarks suggest the potential for an alternate vehicle for addressing brand firms’ concerns about patent certainty, even as work on overall health care reform intensifies.

You may also be interested in...



Abbott's Humira Defense May Be Linked To Counter-Suit In Massachusetts

Abbott is looking to the federal appeals court, and a district court in Massachusetts, to shore up its Humira franchise after a Texas jury issued a $1.67 billion verdict against it, finding that the firm's top-selling drug infringes a patent owned by Johnson & Johnson

Abbott's Humira Defense May Be Linked To Counter-Suit In Massachusetts

Abbott is looking to the federal appeals court, and a district court in Massachusetts, to shore up its Humira franchise after a Texas jury issued a $1.67 billion verdict against it, finding that the firm's top-selling drug infringes a patent owned by Johnson & Johnson

Abbott's Humira Defense Hinges On Appeal - And A Countersuit in Massachusetts

J&J awarded $1.67 billion by Texas jury in patent infringement case; Humira is the subject of three other suits.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel